Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

First Report of PhALLCON: A Phase 3 Study Comparing Ponatinib vs Imatinib in Newly Diagnosed Ph+ ALL

May 19th 2023

Expert Elias Jabbour, MD, reviews clinical data from the PhALLCON study of ponatinib vs imatinib in patients with Ph+ acute lymphocytic leukemia and considers its clinical implications.

Chinese Phase 3 Trial of Roxadustat in Non-Myeloid Malignancies Meets Primary End Point

May 18th 2023

Roxadustat proved to be noninferior to recombinant erythropoietin alfa with regard to change in hemoglobin level from baseline to an average level during weeks 9 to 13 in patients receiving concurrent chemotherapy for non-myeloid malignancies in China, meeting the primary end point of an ongoing phase 3 trial.

FDA Approval Insights: Omidubicel in Blood Cancers Requiring Transplant

May 15th 2023

Dr Horwitz discusses the FDA approval of omidubicel in patients with blood cancers, key efficacy and safety data from the pivotal phase 3 trial, and the benefits omidubicel provides beyond improved neutrophil engraftment.

Ivosidenib Wins European Approval for IDH1-mutated AML and Cholangiocarcinoma

May 10th 2023

The European Commission has approved ivosidenib tablets in combination with azacitidine for the treatment of adult patients with newly diagnosed acute myeloid leukemia with an IDH1 R132 mutation who are not eligible to receive standard induction chemotherapy, and as monotherapy for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an IDH1 R132 mutation who received at least 1 prior line of systemic therapy.

Roxadustat Misses Mark as Anemia Treatment in Transfusion-Dependent, Lower-risk MDS

May 5th 2023

The phase 3 MATTERHORN trial examining roxadustat as an anemia treatment in patients with transfusion-dependent, lower-risk myelodysplastic syndrome did not meet its primary end point.

FDA Grants Priority Review to Luspatercept for First-line Treatment of Anemia in Lower-risk MDS

May 1st 2023

The FDA has granted a priority review to the supplemental biologics license application seeking to expand the current indication of luspatercept to include treatment of anemia in patients with very low- to intermediate-risk myelodysplastic syndrome who have not previously received erythropoiesis-stimulating agents and who may require red blood cell transfusions.

Iptacopan Meets Primary End Point of APPOINT-PNH Trial in Paroxysmal Nocturnal Hemoglobinuria

April 26th 2023

Iptacopan elicited improved hemoglobin levels measuring at least 2 g/dL higher vs baseline, leading to transfusion independence after 24 weeks in approximately 92.2% of patients with complement inhibitor–naïve paroxysmal nocturnal hemoglobinuria.

Sugemalimab Monotherapy Has Clinical Benefit in NK/T-Cell Lymphoma

April 24th 2023

The PD-L1 inhibitor sugemalimab produced durable responses with a tolerable safety profile in patients with relapsed/refractory natural killer/T-cell lymphoma, according to findings from a preplanned primary analysis of the multicenter, single-arm, phase 2 GEMSTONE-201 trial.

FDA Extends Review for Quizartinib in Newly Diagnosed FLT3-ITD+ AML

April 21st 2023

The FDA has extended the review period for a new drug application for quizartinib in combination with standard cytarabine and anthracycline induction and standard cytarabine consolidation chemotherapy, and as continuation monotherapy following consolidation, for the treatment of newly diagnosed adult patients with FLT3-ITD–positive acute myeloid leukemia.

Oncology Financial Navigator Interventions Provide Benefits to Patients With Hematologic Cancers

April 20th 2023

To evaluate the prevalence of financial toxicity and observe the effect of Coverage and Cost-of-Care Links, a program providing financial navigation, investigators initiated a nonrandomized study.

Dr Andreeff on the Rationale for Investigating Uproleselan Plus Venetoclax and Azacitidine in AML

April 19th 2023

Michael Andreeff, MD, PhD, discusses the rationale for investigating uproleselan plus venetoclax and azacitidine in patients with acute myeloid leukemia.

Dr Ball on Prior Research Supporting the SELECT-AML-1 Trial in Newly Diagnosed AML

April 19th 2023

Brian C. Ball, MD, discusses previous research on tamibarotene in newly diagnosed acute myeloid leukemia, and how these data support the ongoing phase 2 SELECT-AML-1 trial.

IDMC Recommends Continuation of REGAL Trial of Galinpepimut-S in AML

April 19th 2023

An independent data monitoring committee has recommended that the phase 3 REGAL trial examining galinpepimut-S in patients with acute myeloid leukemia continue as planned without modifications.

Dr Horwitz on the FDA Approval of Omidubicel in Blood Cancers Requiring Transplant

April 17th 2023

Mitchell E. Horwitz, MD, discusses the significance of omidubicel as an FDA-approved treatment option to reduce the risk of infection in patients with blood cancers and highlights key findings from the pivotal phase 3 trial.

FDA Approves Omidubicel to Reduce Infection Risk in Blood Cancers Requiring Transplant

April 17th 2023

The FDA has approved omidubicel-onlv (Omisirge) to quicken the recovery of neutrophils in the body and reduce the risk of infection in adults and pediatric patients aged 12 years and older with blood cancers who are slated to undergo umbilical cord blood transplantation after a myeloablative conditioning regimen.

Tafasitamab Plus Lenalidomide Has Continued Efficacy and Safety in R/R DLBCL

April 16th 2023

The combination of tafasitamab and lenalidomide followed by tafasitamab maintenance prolonged responses in patients with relapsed/refractory diffuse large B-cell lymphoma.

Dr Christensen on the Influence of Patient Selection for BCL-2 Inhibitor Treatment in AML

April 14th 2023

Bradley W. Christensen, MD, discusses the process of patient selection for BCL-2 induction therapy in patients with acute myeloid leukemia in accordance with their individual disease characteristics.

FDA Places Partial Clinical Hold on Phase 1 Trial of MT-0169 in R/R Myeloma or Non-Hodgkin Lymphoma

April 11th 2023

The FDA has placed a partial clinical hold on a phase 1 trial investigating MT-0169 in patients with relapsed/refractory multiple myeloma or non-Hodgkin lymphoma.

Rapid Advances Shake Up Treatment Considerations in ALL, CML, AML

April 6th 2023

Elias Jabbour, MD; Harry Paul Erba, MD, PhD; Anjali Advani, MD; and Sameem Abedin, MD, discuss key updates pertaining to the leukemia treatment landscape that were presented at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition.

Quizartinib May Represent an Additional Therapeutic Option for FLT3-ITD+ AML

April 3rd 2023

Mark Levis, MD, PhD, discusses potential changes to the FLT3-ITD-mutated acute myeloid leukemia treatment landscape that may occur if the FDA approves quizartinib, key efficacy and safety data with the agent, and how quizartinib compares with midostaurin.